Noveltreat vs Ozempic: Comparison Guide

Noveltreat vs Ozempic: Comparison Guide

If you are comparing Noveltreat and Ozempic, the first thing to know is that Noveltreat is an actual semaglutide brand in India, not a placeholder for future obesity drugs.

This guide compares the two products using the correct brand and formulation context so you can have a more useful conversation with your doctor. Consult your healthcare provider before starting any medication.

What is Ozempic?

Ozempic is Novo Nordisk's brand for semaglutide, a GLP-1 receptor agonist used in adults with type 2 diabetes and widely discussed because semaglutide can also support appetite reduction and weight change.

Ozempic is taken as a once-weekly injection.

What is Noveltreat?

Noveltreat is a Sun Pharma semaglutide injection brand in India, launched on March 21, 2026. Sun Pharma's launch materials describe Noveltreat and Sematrinity as its semaglutide brands in the Indian market: Noveltreat is indicated for chronic weight management in adults (five strengths, 0.25 mg to 2.4 mg weekly), while Sematrinity is indicated for type 2 diabetes.

That means Noveltreat should be discussed as a real branded semaglutide option, not as a hypothetical dual-action or oral next-generation medicine.

What they have in common

Noveltreat and Ozempic share the same active ingredient: semaglutide.

That means both are discussed in relation to:

• slower gastric emptying
• reduced appetite in many users
• weekly injection-based treatment plans

The key difference: approved use and dose

Ozempic is approved for type 2 diabetes, with weekly doses up to 2 mg. Noveltreat is approved for chronic weight management, with weekly doses up to 2.4 mg, so it corresponds more closely to Wegovy than to Ozempic. Sun Pharma's diabetes brand, Sematrinity, is the closer match to Ozempic.

Key differences: Noveltreat vs Ozempic

1. Manufacturer

• Ozempic is made by Novo Nordisk.
• Noveltreat is associated with Sun Pharma in India.

2. Market context

Ozempic is the internationally established originator semaglutide brand. Noveltreat is part of the newer India-market semaglutide rollout from a domestic manufacturer.

3. Access and device workflow

Even with the same active ingredient, pen design, refill process, and local availability can differ between brands. Noveltreat uses a prefilled pen with a concealed needle. At launch, Sun Pharma put Noveltreat's weekly therapy cost at about ₹900 to ₹2,000 depending on dose.

4. Evidence base

The best-known semaglutide trial evidence is tied to the broader originator evidence base. Clinicians still interpret Noveltreat through that semaglutide evidence while also checking local product details and approval context.

Side effects and safety

Because both are semaglutide-based, the expected side-effect profile is broadly similar. Common effects may include:

• nausea
• vomiting
• diarrhoea
• constipation
• abdominal discomfort
• lower appetite

Get urgent medical help for severe stomach pain that does not go away (with or without vomiting, sometimes spreading to the back), signs of a serious allergic reaction, or vomiting or diarrhoea that stops you keeping fluids down. Tell your doctor about upper-right stomach pain or yellowing of the skin or eyes, vision changes if you have diabetes, a lump in your neck, or low blood sugar symptoms if you also take insulin or a sulfonylurea. Do not switch between brands without your doctor, because doses and devices differ.

Bottom line

Noveltreat and Ozempic are both semaglutide injection brands. The main differences are approved use and dose range (weight management up to 2.4 mg for Noveltreat, type 2 diabetes up to 2 mg for Ozempic), plus brand and market context—Sun Pharma's Noveltreat in India versus Novo Nordisk's Ozempic—not a present-versus-future drug comparison.

A clinician can help you compare dosing, device workflow, and access based on your prescription plan. Consult your healthcare provider before starting any medication.

Sources

• https://sunpharma.com/wp-content/uploads/2026/03/PR-for-Semaglutide.pdf
• https://sunpharma.com/wp-content/uploads/2026/03/SEintimationPRforSemaglutide.pdf
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf
• https://cdsco.gov.in/opencms/opencms/en/Home/
• https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
• https://medlineplus.gov/druginfo/meds/a618008.html